Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phenotypic Profile and Molecular Mechanism of Resistance in Carbapenemase-producing Enterobacterales and Pseudomonas Aeruginosa Isolates From Brazilian Hospitals: Implications for the Introduction of IMIPENEM-RELEBACTAM

NCT05285046 is registered in ClinicalTrials.gov with D'Or Institute for Research and Education as lead sponsor.

NCT NCT05285046
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05285046 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phenotypic Profile and Molecular Mechanism of Resistance in Carbapenemase-producing Enterobacterales and Pseudomonas Aeruginosa Isolates From Brazilian Hospitals: Implications for the Introduction of IMIPENEM-RELEBACTAM
Lead sponsor
D'Or Institute for Research and Education
Phase
Observational
Overall status
Unknown status
Start date
April 1, 2022
Completion date
February 28, 2023
Enrollment
250 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

antibiotic resistant infection, bacterial infections